TY - JOUR
T1 - 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis
T2 - Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging
AU - Onel, Karen B.
AU - Horton, Daniel B.
AU - Lovell, Daniel J.
AU - Shenoi, Susan
AU - Cuello, Carlos A.
AU - Angeles-Han, Sheila T.
AU - Becker, Mara L.
AU - Cron, Randy Q.
AU - Feldman, Brian M.
AU - Ferguson, Polly J.
AU - Gewanter, Harry
AU - Guzman, Jaime
AU - Kimura, Yukiko
AU - Lee, Tzielan
AU - Murphy, Katherine
AU - Nigrovic, Peter A.
AU - Ombrello, Michael J.
AU - Rabinovich, C. Egla
AU - Tesher, Melissa
AU - Twilt, Marinka
AU - Klein-Gitelman, Marisa
AU - Barbar-Smiley, Fatima
AU - Cooper, Ashley M.
AU - Edelheit, Barbara
AU - Gillispie-Taylor, Miriah
AU - Hays, Kimberly
AU - Mannion, Melissa L.
AU - Peterson, Rosemary
AU - Flanagan, Elaine
AU - Saad, Nadine
AU - Sullivan, Nancy
AU - Szymanski, Ann Marie
AU - Trachtman, Rebecca
AU - Turgunbaev, Marat
AU - Veiga, Keila
AU - Turner, Amy S.
AU - Reston, James T.
N1 - Funding Information:
Supported by the American College of Rheumatology. Dr. Horton's work was supported by funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH (award K23‐AR‐070286). Dr. Ombrello's work was supported by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH (award AR‐041198).
Publisher Copyright:
© 2022 American College of Rheumatology.
PY - 2022/4
Y1 - 2022/4
N2 - Objective: To provide recommendations for the management of juvenile idiopathic arthritis (JIA) with a focus on nonpharmacologic therapies, medication monitoring, immunizations, and imaging, irrespective of JIA phenotype. Methods: We developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the quality of evidence (high, moderate, low, or very low). A Voting Panel including clinicians and patients/caregivers achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations. Results: Recommendations in this guideline include the use of physical therapy and occupational therapy interventions; a healthy, well-balanced, age-appropriate diet; specific laboratory monitoring for medications; widespread use of immunizations; and shared decision-making with patients/caregivers. Disease management for all patients with JIA is addressed with respect to nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Evidence for all recommendations was graded as low or very low in quality. For that reason, more than half of the recommendations are conditional. Conclusion: This clinical practice guideline complements the 2019 American College of Rheumatology JIA and uveitis guidelines, which addressed polyarthritis, sacroiliitis, enthesitis, and uveitis, and a concurrent 2021 guideline on oligoarthritis, temporomandibular arthritis, and systemic JIA. It serves as a tool to support clinicians, patients, and caregivers in decision-making. The recommendations take into consideration the severity of both articular and nonarticular manifestations as well as patient quality of life. Although evidence is generally low quality and many recommendations are conditional, the inclusion of caregivers and patients in the decision-making process strengthens the relevance and applicability of the guideline. It is important to remember that these are recommendations. Clinical decisions, as always, should be made by the treating clinician and patient/caregiver.
AB - Objective: To provide recommendations for the management of juvenile idiopathic arthritis (JIA) with a focus on nonpharmacologic therapies, medication monitoring, immunizations, and imaging, irrespective of JIA phenotype. Methods: We developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the quality of evidence (high, moderate, low, or very low). A Voting Panel including clinicians and patients/caregivers achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations. Results: Recommendations in this guideline include the use of physical therapy and occupational therapy interventions; a healthy, well-balanced, age-appropriate diet; specific laboratory monitoring for medications; widespread use of immunizations; and shared decision-making with patients/caregivers. Disease management for all patients with JIA is addressed with respect to nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Evidence for all recommendations was graded as low or very low in quality. For that reason, more than half of the recommendations are conditional. Conclusion: This clinical practice guideline complements the 2019 American College of Rheumatology JIA and uveitis guidelines, which addressed polyarthritis, sacroiliitis, enthesitis, and uveitis, and a concurrent 2021 guideline on oligoarthritis, temporomandibular arthritis, and systemic JIA. It serves as a tool to support clinicians, patients, and caregivers in decision-making. The recommendations take into consideration the severity of both articular and nonarticular manifestations as well as patient quality of life. Although evidence is generally low quality and many recommendations are conditional, the inclusion of caregivers and patients in the decision-making process strengthens the relevance and applicability of the guideline. It is important to remember that these are recommendations. Clinical decisions, as always, should be made by the treating clinician and patient/caregiver.
UR - http://www.scopus.com/inward/record.url?scp=85125928734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125928734&partnerID=8YFLogxK
U2 - 10.1002/art.42036
DO - 10.1002/art.42036
M3 - Article
C2 - 35233961
AN - SCOPUS:85125928734
SN - 2326-5191
VL - 74
SP - 570
EP - 585
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 4
ER -